One page takeaway/summary from our 🗣️ with @YJanjigianMD and #MATTERHORN study that resulted in #Durvalumab @FDAOncology approval on November 25, 2025 for resectable GEJ/Gastric adenocarcinoma! #OncTwitter #gism #MedTwitter @OncUpdates

Panic is rampant within the bills mafia this morning.

Teamed up with #BrysonKatona & #LindaLee to make sense of the ever-confusing world of #NETs in our @AGA_Gastro review—hope it helps every GI and Onc specialist who meets these sneaky tumors on a “routine” scope https://t.co/i5KN51TEyy @FoxChaseCancer @PennMedicine @BrighamWomens

Very excited to see this in print. Our latest commentary highlighting the "missing piece of the puzzle" in neuroendocrine neoplasm classification, published in Med @CellPressNews . NENs are classified based on morphology, site of origin, and Ki-67 proliferation indices. These

Reuniting with my colleagues at the U of Miami 🌴 for the international sarcoma conference #CTOS2025. Presenting 4 posters tomorrow 🏃‍♂️😳 @JTrentMDPhD @GinaDAmatoMD1

Thrilled to welcome @AzzaSarfraz to the GI Oncology Research Team at @MiamiCancerInst @BaptistHealthSF @BHCancerCare A physician-scientist from @AKUGlobal joining us from @OhioState, where she focused on GI cancer research. Author of 150+ peer-reviewed publications (h-index

Can beta-blockers enhance the efficacy of immune checkpoint inhibitors? Our new meta-analysis in @TargetOncology @SpringerNature led by Kota Tokunaga, reviews the evidence across solid tumors. Current data show no clear survival benefit—but our ongoing trials will tell us more.

🤩 #ESMO25 GI oncology highlights from @UGrewalMD! ✅ MATTERHORN: Peri-op durvalumab + FLOT→⬆️OS ✅ CARES-009: Camrelizumab + rivoceranib peri-op HCC → EFS 42.1 vs 19.4 mo ✅ STELLAR-303: Zanzalintinib + atezo beats rego in MSS mCRC 💥Full roundup⬇️: https://t.co/DaPQ1mErG4

🎯 Making Sense of GI Cancer Data from #ESMO25 Knowledge is understanding the data. Wisdom is knowing what to do with it. Join global experts as they decode the most impactful updates in GI Oncology — from Upper GI & HPB to CRC & NET. 🗓️ 7 Nov 2025 | 7:00 PM IST 📍 Online Webinar

Excited to do this with some of my most favorite people. Thanks @SuyogCancer for the invitation. Looking forward to a great discussion! @WinshipAtEmory @TheGutOncLab

I just want to give a huge shout out to 2 of the most influential people in my life on their huge achievement of receiving FASCO status. I wouldn’t be where I am without Jimmy Hwang and @DCarrizosaMD; this is but a fraction of the accolades you deserve. @LevineCancer @mpdrc

I’m excited to share the latest episode of #CancerCast where I spoke with @FASinicropeMD from @MayoClinic & Dr. Steven Lipkin from @WeillCornell on #immunotherapy for mismatch repair deficient #ColonCancer and #LynchSyndrome. #Oncoalert #Oncology https://t.co/0rE4rANzzN

Thank you @TargetedOnc for highlighting our work on symptom burden and QoL in early onset NETs using the NET-PRO study. https://t.co/oVR9vv2k65 @WinshipAtEmory @TheGutOncLab

Check out our editorial published in @AnnalsofIM, discussing the ⬆️ global burden of cancer in both young and older adults. There is an ⬆️ need for supportive care specific to the distinctive needs of each population. @efratdotan @FoxChaseCancer https://t.co/bCl7cGD0jn

Back in Austin for round two this year—this time for #NANETS2025. Helped moderate a discussion among my brilliant colleagues, caught up with friends, and heard exciting updates for NET patients. Always a privilege to learn from and with this community. @NANETS1 @UGrewalMD

Honored (and officially feeling distinguished… aka old) to receive the Distinguished Clinician Award from @NANETS1. Thank you @PamelaKunzMD and @efratdotan for the kind words. Grateful and inspired to keep working for better outcomes for pts. @FoxChaseCancer

We are celebrating 👏our @theNCI #GI #SPORE (PI: Bob Coffey). ➡️2011 = 8 GI SPORES ➡️ 2023 = 3 ➡️ 2025 = ONLY 1 SPORE @VUMCDiscoveries 🙏to be part of this #cancerreearch team and the future for #colorectal #cancer! @jordanberlin5 @KristenCiombor @KenLauLab @DrWinkfield

Incredibly honored to receive this recognition from @NANETS1 for our work on equity in the care of patients with Neuroendocrine Neoplasms. This award will serve as a constant reminder for me to continue on this path to ensure that we make progress equitable and available to all

Congrats @NVijayvergiaMD on being awarded the 2025 @NANETS1 Distinguished Clinician Award. You’re truly a leader in our field and such a big inspiration for so many like me. Thanks for your phenomenal and impactful work; this is such a well-deserved honor. @PamelaKunzMD

Preparing for @UTSWHemeOnc @utswcancer Grand Rounds